该股主要指标及行业内排名如下： 迈得医疗2025年三季报显示，前三季度公司主营收入2.25亿元，同比上升2.31%；归母净利润883.67万 元，同比上升15.82%；扣非净利润-127.85万元，同比下降526.58%；其中2025年第三季度，公司单季度 主营收入8364.3万元，同比上升54.38%；单季度归母净利润279.16万元，同比上升224.07%；单季度扣 非净利润123.64万元，同比上升118.23%；负债率29.86%，投资收益16.76万元，财务费用-52.36万元， 毛利率40.19%。迈得医疗（688310）主营业务：医用耗材智能装备的研发、生产、销售和服务,有效整 合医疗器械产品工艺、自动化、软件等方面的技术,形成独特的产品与服务优势,为医用耗材生产企业提 供自动化成套设备和软件服务整体式解决方案。 证券之星消息，截至2026年1月9日收盘，迈得医疗(688310)报收于16.13元，上涨1.13%，换手率1.6%， 成交量2.66万手，成交额4252.79万元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成 ...

证券之星消息，截至2026年1月7日收盘，迈得医疗(688310)报收于15.83元，下跌0.44%，换手率 1.43%，成交量2.37万手，成交额3739.77万元。 | 指标 | 迈得医疗 | 专用设备行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 26.31亿元 | 85.21亿元 | 228 270 | | 净资产 | 8.4亿元 | 23.32亿元 | 204 270 | | 净利润 | 883.67万元 | 9886.83万元 | 190 270 | | 市盈率(动) | 223.32 | 134.42 | 178 270 | | 市净率 | 3.27 | 5.01 | 107 270 | | 毛利率 | 40.19% | 27.79% | 39 270 | | 净利率 | -2.43% | 4.37% | 227 270 | | ROE | 1.1% | 2.67% | 191 270 | 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净齿比 散户净流入 散户净占比 | | | | | | --- ...

证券之星消息，截至2025年12月26日收盘，迈得医疗(688310)报收于15.47元，下跌1.59%，换手率 1.46%，成交量2.43万手，成交额3800.12万元。 12月26日的资金流向数据方面，主力资金净流入315.12万元，占总成交额8.29%，游资资金净流入 234.22万元，占总成交额6.16%，散户资金净流出549.35万元，占总成交额14.46%。 近5日资金流向一览见下表： 迈得医疗2025年三季报显示，前三季度公司主营收入2.25亿元，同比上升2.31%；归母净利润883.67万 元，同比上升15.82%；扣非净利润-127.85万元，同比下降526.58%；其中2025年第三季度，公司单季度 主营收入8364.3万元，同比上升54.38%；单季度归母净利润279.16万元，同比上升224.07%；单季度扣 非净利润123.64万元，同比上升118.23%；负债率29.86%，投资收益16.76万元，财务费用-52.36万元， 毛利率40.19%。迈得医疗（688310）主营业务：医用耗材智能装备的研发、生产、销售和服务,有效整 合医疗器械产品工艺、自动化、软件等方面的技术,形成独特 ...

| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净齿比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-22 | 15.12 -0.26% | | 791.12万 | 13.59% | -18.39万 | -0.32% | -772.72万 | -13.28% | | 2025-12-19 | 15.16 | 2.57% | ● 131.26万 | 3.58% | -320.22万 | -8.73% | 188.96万 | 5.15% | | 2025-12-18 | | 14.78 0.48% | - 19.46万 | 0.46% | -66.43万 | -1.57% | 46.97万 | 1.11% | | 2025-12-17 | 14.71 | 1.03% | 561.11万 | 15.32% | -125.53万 | -3.43% | -435.59万 | -11.89% | | 2025-12-16 | | 14.56 -0.55% | 245.55 ...

证券之星消息，截至2025年12月18日收盘，迈得医疗(688310)报收于14.78元，上涨0.48%，换手率 1.71%，成交量2.84万手，成交额4234.62万元。 12月18日的资金流向数据方面，主力资金净流入19.46万元，占总成交额0.46%，游资资金净流出66.43 万元，占总成交额1.57%，散户资金净流入46.97万元，占总成交额1.11%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-18 | 14.78 0.48% | | 19.46万 | 0.46% | -66.43万 | -1.57% | 46.97万 | 1.11% | | 2025-12-17 | 14.71 | 1.03% | 561.11万 | 15.32% | -125.53万 | -3.43% | -435.59万 | -11.89% | | 2025-12-16 | | 14.56 ...

证券之星消息，截至2025年12月9日收盘，迈得医疗(688310)报收于15.01元，下跌0.86%，换手率 1.39%，成交量2.31万手，成交额3489.02万元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 12月9日的资金流向数据方面，主力资金净流入246.49万元，占总成交额7.06%，游资资金净流入22.84 万元，占总成交额0.65%，散户资金净流出269.33万元，占总成交额7.72%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 迈得医疗2025年三季报显示，前三季度 ...

证券之星消息，截至2025年12月5日收盘，迈得医疗(688310)报收于15.21元，上涨2.08%，换手率 1.98%，成交量3.29万手，成交额4938.04万元。 12月5日的资金流向数据方面，主力资金净流入130.57万元，占总成交额2.64%，游资资金净流入209.15 万元，占总成交额4.24%，散户资金净流出339.72万元，占总成交额6.88%。 近5日资金流向一览见下表： 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 | 指标 | 迈得医疗 | 专用设备行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 25.28亿元 | 76.97亿元 | 231 270 | | 净资产 | 8.4亿元 | 23.32亿元 | 204 270 | | 净利润 | 883.67万元 | 9886.83万元 | 190 270 | | 市盈率(动) | 214.58 | 129.31 | 176 270 | | 市净率 | 3.14 | 4.58 | 106 270 | | 毛利率 | 40.19% | 27.7 ...

证券之星消息，截至2025年12月4日收盘，迈得医疗(688310)报收于14.9元，下跌1.59%，换手率 1.75%，成交量2.9万手，成交额4332.04万元。 12月4日的资金流向数据方面，主力资金净流入689.35万元，占总成交额15.91%，游资资金净流出39.51 万元，占总成交额0.91%，散户资金净流出649.83万元，占总成交额15.0%。 近5日资金流向一览见下表： 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 | 指标 | 迈得医疗 | 专用设备行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 24.77亿元 | 75.15亿元 | 232 270 | | 净 ...

Core Viewpoint - Midea Medical's stock has experienced fluctuations, with a year-to-date increase of 41.57% but a recent decline in the last 5, 20, and 60 trading days [1] Financial Performance - For the period from January to September 2025, Midea Medical achieved a revenue of 225 million yuan, representing a year-on-year growth of 2.31% [2] - The net profit attributable to the parent company was 8.84 million yuan, showing a year-on-year increase of 15.82% [2] Stock Market Activity - As of December 2, Midea Medical's stock price was 15.29 yuan per share, with a market capitalization of 2.54 billion yuan [1] - The stock has seen a net inflow of 353,400 yuan from main funds, with a significant portion of buying activity [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the last occurrence on August 26, where it recorded a net buy of -57.70 million yuan [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 4,528, while the average circulating shares per person decreased by 15.97% to 36,709 shares [2] - The top ten circulating shareholders include notable funds, with some new entrants and exits among them [3] Dividend Distribution - Midea Medical has distributed a total of 202 million yuan in dividends since its A-share listing, with 99.30 million yuan distributed over the past three years [3] Business Overview - Midea Medical, established in March 2003 and listed in December 2019, specializes in the research, production, sales, and service of medical consumables and intelligent equipment [1] - The main revenue sources are safety infusion products (48.75%), blood purification products (26.27%), and other products (24.98%) [1]

Core Viewpoint - As of November 28, 2025, Maide Medical (688310) closed at 16.03 yuan, down 4.53%, with a turnover rate of 4.12% and a trading volume of 68,500 hands, resulting in a transaction amount of 110 million yuan [1] Financial Performance - For the first three quarters of 2025, the company's main revenue was 225 million yuan, an increase of 2.31% year-on-year; the net profit attributable to the parent company was 8.84 million yuan, up 15.82% year-on-year; the non-recurring net profit was -1.28 million yuan, a decrease of 526.58% year-on-year [5] - In Q3 2025, the company's single-quarter main revenue was 83.64 million yuan, an increase of 54.38% year-on-year; the single-quarter net profit attributable to the parent company was 2.79 million yuan, up 224.07% year-on-year; the single-quarter non-recurring net profit was 1.24 million yuan, an increase of 118.23% year-on-year [5] Market Position and Ratios - Maide Medical's total market value is 2.665 billion yuan, with a net asset of 840 million yuan and a net profit of 8.84 million yuan [3] - The company's price-to-earnings ratio (P/E) is 226.15, while the industry average is 130.51; the price-to-book ratio (P/B) is 3.31, compared to the industry average of 4.59 [3] - The gross profit margin is 40.19%, significantly higher than the industry average of 27.79%, while the net profit margin is -2.43%, lower than the industry average of 4.37% [3] Capital Flow - On November 28, 2025, the net inflow of main funds was 14.26 million yuan, accounting for 13.01% of the total transaction amount; the net inflow of retail funds was 1.73 million yuan, accounting for 15.83% of the total transaction amount [1] - In terms of margin trading, the financing buy amounted to 19.92 million yuan, with a net buy of 12.48 million yuan, while there were no securities sold or repaid [2]